Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celiprolol - Acer Therapeutics

Drug Profile

Celiprolol - Acer Therapeutics

Alternative Names: ACER-002; EDSIVO; VASEBRA

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acer Therapeutics
  • Class Antihypertensives; Heart failure therapies; Ischaemic heart disorder therapies; Phenylurea compounds; Propanolamines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ehlers-Danlos syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ehlers-Danlos syndrome

Most Recent Events

  • 01 Oct 2019 Acer Therapeutics completes Type A meeting with the US FDA
  • 13 Aug 2019 Acer Therapeutics plans to conduct a Type A meeting with the US FDA to discuss Complete Response Letter for celiprolol in the third quarter of 2019
  • 25 Jun 2019 Acer Therapeutics receives complete response letter from the FDA for celiprolol in Ehlers-Danlos syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top